Acumen Pharmaceuticals, Inc.

All good things must come to an end, and while the Acumen team is sad to leave #ADPD2026, it’s been a wonderful week of sharing knowledge and innovation in the #Alzheimer’s field. We’ll see you all next year at @adpdnet 2027!

Today at @adpdnet we presented nonclinical findings on our Enhanced Brain Delivery (EBD™) constructs of sabirnetug. The data highlight efforts to advance AD treatment by improving brain penetration through EBD approaches. Learn more: lnkd.in/gsi4TECv

Putting the spotlight on our #ADPD2026 posters! Yesterday, we presented the poster “Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with High Selectivity.” Learn more about our @adpdnet presentations here: lnkd.in/gsi4TECv

We’re excited to share new research at #ADPD2026 this week in Copenhagen & online! Our presentations highlight enhanced brain delivery for sabirnetug, biomarker analyses & development of highly selective anti‑AβO antibodies. Press release: lnkd.in/gsi4TECv

Today we announced a $35.75M private placement to advance potential best‑in‑class molecules from our amyloid beta oligomer‑selective EBD™ portfolio—strengthening our momentum toward improving the lives of those impacted by Alzheimer’s disease. 🔗Link: lnkd.in/gh9Zq438

Acumen’s CMO, Eric Siemers, MD, co‑authored a new paper from the spring 2025 @alzassociation Research Roundtable discussion focused on earlier detection and intervention in Alzheimer’s disease. Now published in Alzheimer’s & Dementia: TRCI. Read more: doi.org/10.1002/trc2.7…

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members & the amazing work they do! 🔗Click here for a look at Yuli's journey & outstanding contributions to our mission: acumenpharm.com/ask-acumen/

We’re excited to be attending this year’s AD/PD Conference. Our presentations highlight our work on enhanced brain delivery (EBD™) and antibody selectivity, advancing how we target toxic Aβ oligomers in Alzheimer’s disease. 🔗Link: investors.acumenpharm.com/news-releases/… #ADPD2026 @adpdnet

Integrity is a cornerstone of our company culture at Acumen. We believe that by conducting ourselves with honesty and transparency, we can build trust and make a lasting impact in the world.  #Integrity #MakingADifference #Values

On National Caregivers Day, we recognize and thank caregivers everywhere for the time, patience, and heart you give to others. We see you, and we’re grateful. #NationalCaregiversDay

At Acumen, we value innovation as a driving force in making a meaningful impact. We believe that by constantly pushing the boundaries of what is possible, we can advance solutions that may improve the lives of those affected by Alzheimer's Disease. #Values #Innovation

Today on the International Day of Women & Girls in Science, we celebrate the women whose leadership & resilience drive progress. We’re grateful to work with women who advance innovation and shape the future of Alzheimer’s research. Their impact lasts far beyond today. #IDWGS

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members & the amazing work they do! 🔗Click here for a look at Kathy's journey & outstanding contributions to our mission: acumenpharm.com/ask-acumen/

This week at the #APDD Summit, Acumen CMO Eric Siemers MD shared how biomarker‑driven antibody innovation is advancing disease‑modifying therapies.

We were proud to see Acumen represented on the keynote stage at #WCBP in D.C. last week. The session highlighted how patient perspectives inform innovation across the biopharmaceutical lifecycle and why patient-centered approaches are essential to progress. @casss_global

At Acumen, our top priority is people. We believe that people are the heart and soul of our company, and we are committed to making a difference in the lives of those impacted by Alzheimer's disease. #values #people #companyvalues

Proud to share a new @ClinicalLeader1 feature on how Acumen is using a “study within a study” approach to better understand Alzheimer’s trial recruitment. Grateful for the thoughtful conversation and the opportunity to contribute to the field. Link: clinicalleader.com/doc/study-with…

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members & the amazing work they do! 🔗Click here for a look at Elizabeth's journey & outstanding contributions to our mission: acumenpharm.com/ask-acumen/

Happy New Year from the Acumen Team - wishing you a healthy and hopeful 2026!

This season, we're grateful for the moments of connection that move us forward, and for the patients, families, and partners who inspire our work every day. Wishing you peace and joy during the holidays, and a hopeful start to the year ahead.